The bispecific antibody avelumab composed of α-MSH analog and PD-L1 antibody may exert a cytotoxic effect, reverse the immune suppression in the tumor environment, and reduce side effects (Zhang et al., 2019) (Figure 1). Here, STAMBP is linked to neoplasm.